Viveve Medical (NASDAQ: VIVE) and Accuray (NASDAQ:ARAY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Viveve Medical and Accuray’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Viveve Medical $7.14 million 14.65 -$20.11 million ($2.12) -2.54
Accuray $383.41 million 1.03 -$29.57 million ($0.34) -13.82

Viveve Medical has higher revenue, but lower earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Viveve Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Viveve Medical has a beta of -0.59, meaning that its share price is 159% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares Viveve Medical and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viveve Medical -266.93% -244.96% -97.99%
Accuray -7.49% -55.91% -6.26%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Viveve Medical and Accuray, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viveve Medical 0 0 4 0 3.00
Accuray 0 3 3 0 2.50

Viveve Medical presently has a consensus price target of $10.50, suggesting a potential upside of 94.81%. Accuray has a consensus price target of $6.60, suggesting a potential upside of 40.43%. Given Viveve Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Viveve Medical is more favorable than Accuray.

Institutional and Insider Ownership

65.5% of Viveve Medical shares are held by institutional investors. Comparatively, 76.6% of Accuray shares are held by institutional investors. 35.1% of Viveve Medical shares are held by company insiders. Comparatively, 3.9% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Accuray beats Viveve Medical on 7 of the 13 factors compared between the two stocks.

Viveve Medical Company Profile

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.